5/14/2008

Biotech firm KAI Pharmaceuticals stands to receive up to nearly $220 million, including $25 million up front, from Bristol-Myers Squibb Co. for the development of KAI-9803, an experimental heart attack drug. The treatment will undergo Phase IIb clinical trials later this year using funds from Bristol-Myers.

Related Summaries